Profile
9.71 -0.22(-2.22%)05/17/2024
Vir Biotechnology Inc (VIR)
Vir Biotechnology Inc (VIR)
| Stock Exchange | United States (NASDAQ) |
| Sector | Healthcare |
| Industry | Biotechnology |
| Type | Equity Shares |
| CEO | Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. |
| # of Employees | 587 |
| Website | https://www.vir.bio |
| CIK | 1706431.0 |
| FIGI | BBG00Q5FZ969 |
| Composite Ticker | VIR:US |
| Share Class FIGI | BBG00H2QQ8V2 |
| Frist Price Date | 2019-10-11 |
| Last Price Date | 2024-05-17 |
| Business Description Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California. | |